Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study.
AMI, acute myocardial infarction
CV, cardiovascular
MI, myocardial infarction
SEER, Surveillance, Epidemiology, and End Results
cancer survivorship
coronary artery disease
epidemiology
heart failure
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
14
09
2021
revised:
18
01
2022
accepted:
19
01
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Patients with cancer and cancer survivors are at increased risk for incident heart failure, but there are conflicting data on the long-term risk for other cardiovascular events and how such risk may vary by cancer site. The aim of this study was to determine the impact of a new cancer diagnosis on the risk for fatal and nonfatal cardiovascular events. Using administrative health care databases, a population-based retrospective cohort study was conducted among 4,519,243 adults residing in Alberta, Canada, from April 2007 to December 2018. Participants with new cancer diagnoses during the study period were compared with those without cancer with respect to risk for subsequent cardiovascular events (cardiovascular mortality, myocardial infarction, stroke, heart failure, and pulmonary embolism) using time-to-event survival models after adjusting for sociodemographic data and comorbidities. A total of 224,016 participants with new cancer diagnoses were identified, as well as 73,360 cardiovascular deaths and 470,481 nonfatal cardiovascular events during a median follow-up period of 11.8 years. After adjustment, participants with cancer had HRs of 1.33 (95% CI: 1.29-1.37) for cardiovascular mortality, 1.01 (95% CI: 0.97-1.05) for myocardial infarction, 1.44 (95% CI: 1.41-1.47) for stroke, 1.62 (95% CI: 1.59-1.65) for heart failure, and 3.43 (95% CI: 3.37-3.50) for pulmonary embolism, compared with participants without cancer. Cardiovascular risk was highest for patients with genitourinary, gastrointestinal, thoracic, nervous system and hematologic malignancies. A new cancer diagnosis is independently associated with a significantly increased risk for cardiovascular death and nonfatal morbidity regardless of cancer site. These findings highlight the need for a collaborative approach to health care for patients with cancer and cancer survivors.
Sections du résumé
Background
UNASSIGNED
Patients with cancer and cancer survivors are at increased risk for incident heart failure, but there are conflicting data on the long-term risk for other cardiovascular events and how such risk may vary by cancer site.
Objectives
UNASSIGNED
The aim of this study was to determine the impact of a new cancer diagnosis on the risk for fatal and nonfatal cardiovascular events.
Methods
UNASSIGNED
Using administrative health care databases, a population-based retrospective cohort study was conducted among 4,519,243 adults residing in Alberta, Canada, from April 2007 to December 2018. Participants with new cancer diagnoses during the study period were compared with those without cancer with respect to risk for subsequent cardiovascular events (cardiovascular mortality, myocardial infarction, stroke, heart failure, and pulmonary embolism) using time-to-event survival models after adjusting for sociodemographic data and comorbidities.
Results
UNASSIGNED
A total of 224,016 participants with new cancer diagnoses were identified, as well as 73,360 cardiovascular deaths and 470,481 nonfatal cardiovascular events during a median follow-up period of 11.8 years. After adjustment, participants with cancer had HRs of 1.33 (95% CI: 1.29-1.37) for cardiovascular mortality, 1.01 (95% CI: 0.97-1.05) for myocardial infarction, 1.44 (95% CI: 1.41-1.47) for stroke, 1.62 (95% CI: 1.59-1.65) for heart failure, and 3.43 (95% CI: 3.37-3.50) for pulmonary embolism, compared with participants without cancer. Cardiovascular risk was highest for patients with genitourinary, gastrointestinal, thoracic, nervous system and hematologic malignancies.
Conclusions
UNASSIGNED
A new cancer diagnosis is independently associated with a significantly increased risk for cardiovascular death and nonfatal morbidity regardless of cancer site. These findings highlight the need for a collaborative approach to health care for patients with cancer and cancer survivors.
Identifiants
pubmed: 35492824
doi: 10.1016/j.jaccao.2022.01.100
pii: S2666-0873(22)00111-9
pmc: PMC9040097
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85-94Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Research support was provided (to Dr Tonelli) by a foundation grant from the Canadian Institutes of Health Research. Dr Tonelli was supported by the David Freeze Chair in Health Services Research at the University of Calgary. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the paper; or decision to submit the manuscript for publication. This study is based in part by data provided by Alberta Health and Alberta Health Services. The interpretation and conclusions contained herein are those of the researchers and do not represent the views of the government of Alberta or Alberta Health Services. Neither the government of Alberta nor Alberta Health or Alberta Health Services expresses any opinion in relation to this study. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
BMC Cancer. 2020 Aug 12;20(1):751
pubmed: 32787791
Stroke. 2005 Aug;36(8):1776-81
pubmed: 16020772
JACC CardioOncol. 2021 Apr 20;3(2):205-218
pubmed: 34396325
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Can J Public Health. 2013 Apr 24;104(3):e252-7
pubmed: 23823891
Lancet. 2012 Sep 1;380(9844):807-14
pubmed: 22717317
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
Mayo Clin Proc. 2016 Dec;91(12):1675-1677
pubmed: 27916153
Prog Cardiovasc Dis. 2019 Mar - Apr;62(2):116-126
pubmed: 30797800
J Clin Oncol. 2016 Jul 1;34(19):2239-46
pubmed: 27091709
J Thromb Haemost. 2008 May;6(5):772-80
pubmed: 18318689
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
JAMA Netw Open. 2019 Aug 2;2(8):e1910456
pubmed: 31469399
Am Heart J. 2002 Aug;144(2):290-6
pubmed: 12177647
Health Serv Res. 2008 Aug;43(4):1424-41
pubmed: 18756617
Front Oncol. 2021 Jan 25;10:586401
pubmed: 33569344
BMC Med Res Methodol. 2013 Dec 07;13:152
pubmed: 24314264
BMC Nephrol. 2009 Oct 19;10:30
pubmed: 19840369
Can J Cardiol. 2018 Mar;34(3):281-287
pubmed: 29395702
Circulation. 2019 Mar 26;139(13):e579-e602
pubmed: 30786722
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
BMJ. 2012 Aug 29;345:e5287
pubmed: 22936784
Eur Heart J. 2018 Nov 14;39(43):3896-3903
pubmed: 29635274
Can J Cardiol. 2016 Nov;32(11):1263-1282
pubmed: 27712954
BMC Med Inform Decis Mak. 2015 Apr 17;15:31
pubmed: 25886580
JAMA Netw Open. 2018 Nov 2;1(7):e184852
pubmed: 30646392